GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » Operating Margin %

PhaseBio Pharmaceuticals (PhaseBio Pharmaceuticals) Operating Margin %

: -12,169.23% (As of Jun. 2022)
View and export this data going back to 2018. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. PhaseBio Pharmaceuticals's Operating Income for the three months ended in Jun. 2022 was $-25.31 Mil. PhaseBio Pharmaceuticals's Revenue for the three months ended in Jun. 2022 was $0.21 Mil. Therefore, PhaseBio Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 was -12,169.23%.

The historical rank and industry rank for PhaseBio Pharmaceuticals's Operating Margin % or its related term are showing as below:


PHASQ's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -178.545
* Ranked among companies with meaningful Operating Margin % only.

PhaseBio Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

PhaseBio Pharmaceuticals's Operating Income for the three months ended in Jun. 2022 was $-25.31 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2022 was $-104.20 Mil.


PhaseBio Pharmaceuticals Operating Margin % Historical Data

The historical data trend for PhaseBio Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Premium Member Only - -2,940.72 -1,683.02 - -991.25

PhaseBio Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -203.65 -8,530.15 -20,307.59 -15,579.49 -12,169.23

Competitive Comparison

For the Biotechnology subindustry, PhaseBio Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhaseBio Pharmaceuticals Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where PhaseBio Pharmaceuticals's Operating Margin % falls into.



PhaseBio Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

PhaseBio Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-107.362 / 10.831
=-991.25 %

PhaseBio Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=-25.312 / 0.208
=-12,169.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhaseBio Pharmaceuticals  (OTCPK:PHASQ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


PhaseBio Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseBio Pharmaceuticals (PhaseBio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Executives
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt officer: VP, Human Resources C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall officer: Chief Commercial Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance officer: VP, Research and Sci. Affairs C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York officer: VP, Corporate Development C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee officer: Chief Medical Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold officer: VP, Preclinical and Chem C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson officer: VP, Head of Legal C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355

PhaseBio Pharmaceuticals (PhaseBio Pharmaceuticals) Headlines

From GuruFocus

PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

By Business Wire Business Wire 04-04-2022